Literature DB >> 14523389

Individuality: the barrier to optimal immunosuppression.

Barry D Kahan1.   

Abstract

Immunosuppressive therapy aims to protect transplanted organs from host responses. Individuals have unique repertoires of responses to foreign antigens and toxic reactions to immunosuppressants; the former determining the type or intensity of rejection reactions and the latter influencing the severity of iatrogenic effects. Because existing agents target molecules that are widely distributed in tissues, new strategies must selectively block lymphoid cells only, disrupt alloresponses but not innate immune responses, interact synergistically with other agents, facilitate the homeostatic process that naturally leads to graft acceptance and ideally only interrupt donor-specific responses. Approaches presently under investigation aim to alter cell trafficking, or selectively deviate the maturation of antigen-presenting cells or inhibit lymphocyte-activation cascades - events that are crucial to rejection responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14523389     DOI: 10.1038/nri1204

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  26 in total

Review 1.  Molecular diagnostics in transplantation.

Authors:  Maarten Naesens; Minnie M Sarwal
Journal:  Nat Rev Nephrol       Date:  2010-08-24       Impact factor: 28.314

Review 2.  Extracellular Matrix Bioscaffolds as Immunomodulatory Biomaterials<sup/>.

Authors:  Jenna L Dziki; Luai Huleihel; Michelle E Scarritt; Stephen F Badylak
Journal:  Tissue Eng Part A       Date:  2017-05-19       Impact factor: 3.845

3.  Evaluation of alloreactivity in kidney transplant recipients treated with antithymocyte globulin versus IL-2 receptor blocker.

Authors:  L Cherkassky; M Lanning; P N Lalli; J Czerr; H Siegel; L Danziger-Isakov; T Srinivas; A Valujskikh; D A Shoskes; W Baldwin; R L Fairchild; E D Poggio
Journal:  Am J Transplant       Date:  2011-05-12       Impact factor: 8.086

4.  LY294002 and rapamycin co-operate to inhibit T-cell proliferation.

Authors:  Elaine M Breslin; Paul C White; Angharad M Shore; Mathew Clement; Paul Brennan
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

5.  Phytotoxic, Antifungal and Immunosuppressive Metabolites from Aspergillus terreus QT122 Isolated from the Gut of Dragonfly.

Authors:  Yi-Hui Lu; Li-Ping Jin; Li-Chun Kong; Ying-Lao Zhang
Journal:  Curr Microbiol       Date:  2016-11-14       Impact factor: 2.188

Review 6.  Mesenchymal stem cells as a therapeutic tool to treat sepsis.

Authors:  Eleuterio Lombardo; Tom van der Poll; Olga DelaRosa; Wilfried Dalemans
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

7.  The calcineurin pathway inhibitor tacrolimus enhances the in vitro activity of azoles against Mucorales via apoptosis.

Authors:  F Shirazi; D P Kontoyiannis
Journal:  Eukaryot Cell       Date:  2013-07-12

8.  Trichomide A, a natural cyclodepsipeptide, exerts immunosuppressive activity against activated T lymphocytes by upregulating SHP2 activation to overcome contact dermatitis.

Authors:  Xingqi Wang; Aihua Zhang; Jian Gao; Wei Chen; Shiyu Wang; Xuefeng Wu; Yan Shen; Yuehai Ke; Zichun Hua; Renxiang Tan; Yang Sun; Qiang Xu
Journal:  J Invest Dermatol       Date:  2014-06-16       Impact factor: 8.551

9.  Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis.

Authors:  Russell E Lewis; Ronen Ben-Ami; Leyla Best; Nathaniel Albert; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2012-12-13       Impact factor: 5.226

Review 10.  Current concepts and perspectives of immunosuppression in organ transplantation.

Authors:  Marcus N Scherer; Bernhard Banas; Kiriaki Mantouvalou; Andreas Schnitzbauer; Aiman Obed; Bernhard K Krämer; Hans J Schlitt
Journal:  Langenbecks Arch Surg       Date:  2007-04-21       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.